"b cell" trang 4 - tải miễn phí từ tailieunhanh
DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation

DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation
10    30    1
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: Long-term results from a single center in China

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: Long-term results from a single center in China
11    39    1
Clinical characteristics and prognostic factors of bone lymphomas: Focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas

Clinical characteristics and prognostic factors of bone lymphomas: Focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas
9    55    1
Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas

Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas
10    33    1
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: A population-based analysis

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: A population-based analysis
11    47    1
Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: A prospective, observational study

Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: A prospective, observational study
6    40    1
Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
11    50    1
Standard b-value versus low b-value diffusion-weighted MRI in renal cell carcinoma: A systematic review and meta-analysis

Standard b-value versus low b-value diffusion-weighted MRI in renal cell carcinoma: A systematic review and meta-analysis
8    41    1
Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma

Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma
6    72    1
SEPIa, a knowledge-driven algorithm for predicting conformational B-cell epitopes from the amino acid sequence

SEPIa, a knowledge-driven algorithm for predicting conformational B-cell epitopes from the amino acid sequence
12    30    1
A meta-learning approach for B-cell conformational epitope prediction

A meta-learning approach for B-cell conformational epitope prediction
15    55    1
EPMLR: Sequence-based linear B-cell epitope prediction method using multiple linear regression

EPMLR: Sequence-based linear B-cell epitope prediction method using multiple linear regression
6    61    1
The TRACTISS Protocol: A randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome

The TRACTISS Protocol: A randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome
10    45    1
Network meta-analysis of targeted therapies for diffuse large B cell lymphoma

Network meta-analysis of targeted therapies for diffuse large B cell lymphoma
10    28    1
Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a populationbased study

Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a populationbased study
12    44    1
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)
11    38    1
Clinical and prognostic features of non hodgkin lymphoma and preliminary effective evaluation of R-chop regimen in patients with diffuse large B-cell lymphoma

Clinical and prognostic features of non hodgkin lymphoma and preliminary effective evaluation of R-chop regimen in patients with diffuse large B-cell lymphoma
8    65    1
Inferring B cell specificity for vaccines using a Bayesian mixture model

Inferring B cell specificity for vaccines using a Bayesian mixture model
11    43    2
Genetic alterations in B cell lymphoma subtypes as potential biomarkers for noninvasive diagnosis, prognosis, therapy, and disease monitoring

Genetic alterations in B cell lymphoma subtypes as potential biomarkers for noninvasive diagnosis, prognosis, therapy, and disease monitoring
14    42    1
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma

Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma
14    56    1